Literature DB >> 24426123

Expression, Identification and Characterize of CD25-Binding Epitope Modified Human IL-2 in Pichia pastoris.

S Wang1, H T Li1, Y H Liu1, Y Z Zhu1, W H Wang1, Y X An1, L G Miao1.   

Abstract

Interleukin-2 (IL-2) plays important roles in variety of immune functions and it is widely used in the medication. But in recent years it was reported that vascular leak syndrome (VLS) was induced by IL-2. Evidences showed that the interaction of IL-2 and IL-2Rαβγ (CD25) caused VLS. Thus, this experiment modified the CD25-binding epitope in human IL-2 (hIL-2) to minimize the side effect of IL-2 in the medication. In this study, a recombinant human interleukin 2 (rhIL-2) was expressed in Pichia (P.) pastoris. An effective strategy was established to express rhIL-2 protein in 120 L scale and the optimal purification procedure was investigated. The purity of rhIL-2 in final product was about 98 % and the concentration of the rhIL-2 was 0.45 mg/mL. Bioactivity analysis showed that the purified rhIL-2 protein displayed high activity on proliferation of CTLL-2 cells and increased the ratio of CD4(+)/CD8(+). It indicates that the target protein is expressed and the character of the rhIL-2 has high activity. This study provides a strategy for large-scale production of bioactive rhIL-2 protein using P. pastoris as an expression host.

Entities:  

Keywords:  Expression; IL-2; Immune function; Purification

Year:  2013        PMID: 24426123      PMCID: PMC3689400          DOI: 10.1007/s12088-013-0366-3

Source DB:  PubMed          Journal:  Indian J Microbiol        ISSN: 0046-8991            Impact factor:   2.461


  16 in total

Review 1.  Managing toxicities of high-dose interleukin-2.

Authors:  Rowena N Schwartz; Lori Stover; Janice P Dutcher
Journal:  Oncology (Williston Park)       Date:  2002-11       Impact factor: 2.990

2.  Pharmacokinetics of recombinant interleukin 2 in humans.

Authors:  M W Konrad; G Hemstreet; E M Hersh; P W Mansell; R Mertelsmann; J E Kolitz; E C Bradley
Journal:  Cancer Res       Date:  1990-04-01       Impact factor: 12.701

3.  In vivo CD4+ T-cell up-regulation and high dose side effects of refolded duck interleukin-2.

Authors:  Jinyong Wang; Jing Qi; Huigang Shen; Jiyong Zhou; Jie Fang; Hongxun Chen; Zhiping Wang; Hongliang Li
Journal:  Cytokine       Date:  2006-08-01       Impact factor: 3.861

4.  Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells.

Authors:  Carsten Krieg; Sven Létourneau; Giuseppe Pantaleo; Onur Boyman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-14       Impact factor: 11.205

5.  Suppressive effects of aluminum trichloride on the T lymphocyte immune function of rats.

Authors:  Yanzhu Zhu; Chongwei Hu; Xinwei Li; Bing Shao; Hao Sun; Hansong Zhao; Yanfei Li
Journal:  Food Chem Toxicol       Date:  2011-12-16       Impact factor: 6.023

Review 6.  Heterologous protein production using the Pichia pastoris expression system.

Authors:  Sue Macauley-Patrick; Mariana L Fazenda; Brian McNeil; Linda M Harvey
Journal:  Yeast       Date:  2005-03       Impact factor: 3.239

7.  Expression, purification, and characterization of a functional mutant recombinant human interleukin-2.

Authors:  Mingjun Liu; Bin Wang; Guirong Sun; Dongmeng Qian; Zhiyong Yan; Xuxia Song; Shouyi Ding
Journal:  Protein Pept Lett       Date:  2010-10       Impact factor: 1.890

8.  Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo.

Authors:  Joseph N Blattman; Jason M Grayson; E John Wherry; Susan M Kaech; Kendall A Smith; Rafi Ahmed
Journal:  Nat Med       Date:  2003-04-14       Impact factor: 53.440

9.  Comparative tissue distribution of 125I- and U-14C-labeled recombinant human interleukin-2 in the rat.

Authors:  J Sabo; G Ni; R Nadeau; D J Liberato; A Loh
Journal:  Lymphokine Cytokine Res       Date:  1992-08

Review 10.  Application of IL-2 therapy to target T regulatory cell function.

Authors:  Ethan M Shevach
Journal:  Trends Immunol       Date:  2012-08-30       Impact factor: 16.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.